The news. The narrative. The timeline.
AP frames a 27-state recall while FDA's corrected laboratory record has no confirmed positive product sample; urgency does not license certainty.
AP emphasizes the 27-state recall while FDA's corrected page separates protective action from absent laboratory confirmation.
FDA's verified post supports the recall and potential-contamination warning, not a laboratory result.
NPR leads with deaths and retaliation while CENTCOM frames punishment and shipping protection; both leave authority, damage standards and an exit unstated.
The European Commission calls two Google measures binding; treating that official frame as compliance hides price, eligibility, anonymization, uptake and appeal.
The Guardian leads with Vingegaard's crash and Evenepoel's win; blaming the 2 a.m. test hides the unpublished suspicion, approval chain and remedy.
The Guardian frames a nostalgic fee appeal while the BBC reports shrinking licences; taste talk hides who pays and which services or jobs bear reform.
The Guardian frames a response to two fatal stops while Homan calls cameras officer protection; announcement coverage hides activation, disclosure and discipline.
The Guardian invokes Mapplethorpe lineage; that style frame hides sitter consent, ownership and preservation rights across Wood's 20-box archive.
BBC and NPR frame an airport release while exile was reportedly a condition; calling departure freedom hides consent, parole and return rights.
NPR frames multimillion-dollar clemency fees as an access industry; treating fees as outcomes hides contracts, contacts, recommendations and refunds.
BBC frames cash's return as wartime strain while Russian security logic treats shutdowns as defense; merging them hides payment failures, taxes and regions.
Financial Times frames Apple's letters as a widening trade-secret fight; theft or intimidation verdicts hide what preserved records and discovery prove.
Google News headlines frame an EY breach while California's filing points to a vendor system; collapsing them distorts scope and client action.
Fandom sees a blockbuster, but CNBC's studio estimate shows premium prices and scarce screens concentrating access before final gross or profit exists.
A release promotes an inexpensive long-COVID option, but one Brazilian trial measured fatigue relief, not a cure, approval or durable benefit.